Twist expects Revelar to begin clinical studies of the antibody in 2022. It will also license up to five additional antibodies developed by Twist over the next four years. Twist may receive milestone payments from Revelar of more than $100 million for development, regulatory, and commercial milestones, it said.

Twist launches exome panel for genomics research
Twist Bioscience has launched Exome 2.0, an exome panel for genomics research.

Twist Bioscience, Broad Institute partner
Twist Bioscience and the Broad Institute have created a custom next-generation sequencing target enrichment exome panel to be used to research cancer...

Twist, Centogene to develop rare disease assay kits
Twist Bioscience and Centogene have signed a contract to collaborate on the development and commercialization of custom assay kits for rare diseases.

Twist Bioscience expands Alliance Panel
Twist Bioscience has expanded its Alliance Panel offering to include products designed by expert collaborators that have a wide range of clinical applications.

Twist, DeepCDR collaborate on antibody libraries
Twist Bioscience announced it is collaborating with DeepCDR to apply deep-learning algorithms to Twist's antibody discovery and optimization capabilities.